Novartis' new Gilenya data fails to address NICE concerns as final decision looms
This article was originally published in Scrip
Novartis has released a basket of clinical and preclinical data to support Gilenya (fingolimod), the first oral treatment for multiple sclerosis that was approved in the US last year and in the EU in March 2011. The firm has collated a range of data under the headline figure that the drug has had "more than 20,000 patient-years of exposure", making the announcement at a critical point in the product's European career.
You may also be interested in...
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.